Apimeds Pharmaceuticals US (APUS) Total Non-Current Liabilities (2023 - 2025)
Apimeds Pharmaceuticals US (APUS) reported Total Non-Current Liabilities of $9.2 million for Q4 2025, up 1352.75% quarter-over-quarter from $634589.0 in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US has reported Total Non-Current Liabilities for 2 years, with the latest figure at $9.2 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to $9.2 million; the trailing twelve-month figure through Dec 2025 stood at $9.2 million (changed N/A YoY), and the FY2025 full-year result was $9.2 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $9.2 million, up from $634589.0 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $9.2 million in Q4 2025, with the low at $321329.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Apimeds Pharmaceuticals US | 13.93 Mn | 10.29 Mn | - | 9.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.22 Mn |
| Jun 30, 2025 | 634,589.00 |
| Dec 31, 2023 | 321,329.00 |